Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus SODIUM ROSE BENGAL I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 CHLORIDE versus SODIUM ROSE BENGAL I 131.
INDIUM IN 111 CHLORIDE vs SODIUM ROSE BENGAL I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 chloride is a radiopharmaceutical that emits gamma radiation. It binds to transferrin in the blood and is taken up by certain cells, allowing imaging of the reticuloendothelial system or labeled cells.
Sodium rose bengal I 131 is a radioactive diagnostic agent that is taken up by hepatocytes and excreted into the bile, allowing imaging of the hepatobiliary system. The radioactive iodine (I-131) emits gamma rays, which can be detected externally to assess liver and gallbladder function.
Intravenous administration of 1.0 mCi (37 MBq) for routine imaging; dose may range from 0.5 to 2.0 mCi (18.5 to 74 MBq) depending on imaging protocol.
5-50 µCi (0.185-1.85 MBq) intravenous bolus for hepatic function imaging. For functional imaging of hepatobiliary system, typical dose: 150-300 µCi (5.55-11.1 MBq) IV.
None Documented
None Documented
Physical half-life: 2.804 days (67.3 hours). Biological half-life: 50-100 days for retained fraction. Effective half-life (combined): ~2.7 days for early phase, prolonged for bone marrow.
Terminal elimination half-life is approximately 3-7 days, reflecting slow clearance from the liver and bile.
Renal (90% over 48 hours), fecal (<1% as unchanged). The remainder is retained in organs (liver, spleen, bone marrow) with slow release.
Primarily hepatic excretion into bile (90-95%), with minimal renal excretion (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical